Scandinavian ChemoTech AB Series B (CMOTEC-B) — Working Capital to Net Assets Ratio
Scandinavian ChemoTech AB Series B (CMOTEC-B) has a Working Capital to Net Assets ratio of -117.0% as of June 2026. Working capital of Skr-1.78 Million (current assets of Skr7.71 Million minus current liabilities of Skr9.49 Million) is measured against net assets of Skr1.52 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Scandinavian ChemoTech AB Series B defensive interval ratio to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Scandinavian ChemoTech AB Series B Working Capital to Net Assets (2014–2025)
This chart shows how Scandinavian ChemoTech AB Series B's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at -117.0%, reflecting working capital of Skr-1.78 Million against net assets of Skr1.52 Million SEK. For the complete balance sheet picture, see CMOTEC-B total asset value.
Annual Working Capital to Net Assets for Scandinavian ChemoTech AB Series B (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Scandinavian ChemoTech AB Series B from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read Scandinavian ChemoTech AB Series B (CMOTEC-B) total liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -27.5% | Skr-876.00K | Skr3.19 Million | Skr9.14 Million | Skr10.01 Million | ▼ -33.7 pp |
| 2024 | 6.2% | Skr370.00K | Skr5.98 Million | Skr7.77 Million | Skr7.40 Million | ▼ -24.3 pp |
| 2023 | 30.5% | Skr3.36 Million | Skr11.03 Million | Skr7.20 Million | Skr3.84 Million | ▲ +1.1 pp |
| 2022 | 29.4% | Skr4.11 Million | Skr13.99 Million | Skr11.82 Million | Skr7.71 Million | ▼ -18.9 pp |
| 2021 | 48.3% | Skr11.54 Million | Skr23.92 Million | Skr13.44 Million | Skr1.89 Million | ▲ +76.1 pp |
| 2020 | -27.8% | Skr-2.57 Million | Skr9.24 Million | Skr4.13 Million | Skr6.70 Million | ▼ -6.3 pp |
| 2019 | -21.6% | Skr-2.10 Million | Skr9.73 Million | Skr5.53 Million | Skr7.63 Million | ▼ -52.2 pp |
| 2018 | 30.6% | Skr6.27 Million | Skr20.50 Million | Skr8.29 Million | Skr2.02 Million | ▼ -0.6 pp |
| 2017 | 31.2% | Skr3.21 Million | Skr10.29 Million | Skr5.32 Million | Skr2.11 Million | ▼ -40.3 pp |
| 2016 | 71.5% | Skr10.43 Million | Skr14.58 Million | Skr12.15 Million | Skr1.72 Million | ▲ +235.9 pp |
| 2015 | -164.4% | Skr-1.43 Million | Skr868.64K | Skr3.61 Million | Skr5.03 Million | ▼ -219.2 pp |
| 2014 | 54.7% | Skr25.33K | Skr46.27K | Skr44.96K | Skr19.63K | — |